Shionogi/Merck HIV Patent Tussle Set To Go Another Round
Executive Summary
Shionogi has vowed to appeal a ruling by a court in the UK that a patent relating to HIV integrase inhibitors is invalid, as an ongoing European intellectual property tussle with rival Merck & Co gathers steam.
You may also be interested in...
German Isentress Case Could Mean More Compulsory Licensing In Europe
A German court’s decision to uphold a compulsory license allowing Merck & Co to keep on selling its HIV drug Isentress could pave the way for more compulsory licensing in Europe.
Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
Company hopes TAF-based combo incorporating integrase inhibitor bictegravir can help it compete with ViiV, but beyond that pipeline holds only early-stage and smaller opportunities in HIV. Analysts call on Gilead to use its cash stockpile to find its next R&D focus.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.